>

Michael Berelowitz - KAMADA Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 2,071  34.00  1.67%

  Director
Dr. Michael Berelowitz was appointed Director at Kamada Ltd effective August 4, 2015. Dr. Berelowitz has over 40 years of clinical development and academic research experience, including 5 years of pharmaceutical development experience with Pfizer, Inc. Prior to that, Dr. Berelowitz spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine
Age: 73  Director Since 2015  Ph.D    
(972) 8 9406472  www.kamada.com
Berelowitz serves as a biopharmaceuticals consultant. He holds Directorship Oramed Pharmaceuticals, Recro Pharma, Inc. and DIR Technologies. Additionally, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society, Metacure, Ltd., Haptocure, Ltd., and has chaired the Task Force on Research of the New York State Council on Diabetes.Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town.

Management Efficiency

The company has accumulated 5.75 M in total debt with debt to equity ratio (D/E) of 4.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. KAMADA has Current Ratio of 6.02 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Sanford ZweifachCOMPUGEN
2018
Eran PerryCOMPUGEN
2019
Yigal FatranKADIMASTEM
2014
Michal PremingerCOMPUGEN
2017
Ziv KopEVOGENE LTD
2014
Simcha RockKITOV PHARMA LTD
2018
Leah BruckKITOV PHARMA LTD
2016
Gilead HalevyCOMPUGEN
2018
Daniel PelegSOLEGREEN LTD
2017
Avner NavehSOLEGREEN LTD
Adrian PercyEVOGENE LTD
2019
Arie OvadiaCOMPUGEN
2007
Ehood NisanSOLEGREEN LTD
2016
Aharon SchwartzPROTALIX BIOTHERAP
2014
Kinneret SavitzkyEVOGENE LTD
2010
Ruth ArnonCOMPUGEN
2007
Yoav KedarSOLEGREEN LTD
2012
Hillel RozanskiSOLEGREEN LTD
2018
Leon RecanatiEVOGENE LTD
2005
Arie WeberKITOV PHARMA LTD
2017
Avi BzuraKADIMASTEM
2013

Company Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.KAMADA (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 429 people.

KAMADA Leadership Team

Pnina Strauss, Vice President - Inhalation programs & IPView
Itzhak Krinsky, DirectorView
Barak Bashari, Vice President - OperationsView
Eran Schenker, Vice President - Medical DirectorView
Tuvia Shoham, Independent DirectorView
Michal Stein, Vice President and Medical Director for ImmunologyView
Shani Dotan, Vice President of Human ResourcesView
Liliana Bar, VP of RandDView
Yael Brenner, Vice President - QualityView
Abraham Havron, Independent DirectorView
Asaf Frumerman, DirectorView
Ruth Wolfson, Senior Vice President - Scientific AffairsView
Shmuel Rubinstein, DirectorView
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary DiseasesView
Michael Berelowitz, DirectorView
David Tsur, Co-Founder and Deputy Executive ChairmanView
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&DView
Leon Recanati, Chairman of the BoardView
Gil Efron, CFO, Principal Accounting Officer and Deputy CEOView
Jonathan Hahn, DirectorView
Eran Schenkar, Vice President - Medical DirectorView
Gwen Melincoff, DirectorView
Chaime Orlev, Chief Financial OfficerView
Michal Ayalon, Vice President - Research & DevelopmentView
Amir London, Chief Executive OfficerView
Estery GilozRan, Independent DirectorView
Reuven Behar, DirectorView
Eitan Kyiet, Vice President - Business DevelopmentView
Ziv Kop, DirectorView

Stock Performance Indicators

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page